Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of Tenalisib (RP6530) in Combination With Romidepsin in Patients With Relapsed/Refractory T-cell Lymphoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Pathologically confirmed T-cell lymphomas at the enrolling institution.~2. Disease status as defined as relapsed or progressed patients who have received at least one systemic therapy.~3. The patients should have received NOT more than three prior systemic combination chemotherapies~4. PTCL patients must have measurable disease defined as at least one bidimensional measurable lesion with minimum measurement of \> 1.5 cm in the longest diameter.~5. Must have ECOG performance status ≤ 2~6. Adequate bone marrow, liver and renal function in line with below mentioned laboratory requirements.~   1. Hemoglobin ≥8.0 g/dL~  2. Absolute neutrophil count (ANC) ≥1,000/µL~  3. Platelet count ≥75,000/μL~  4. Total bilirubin ≤1.5 times the ULN (or ≤3 x ULN, if patient has Gilbert syndrome)~  5. AST (SGOT) and ALT (SGPT) ≤ 3 x ULN; ≤ 5 ULN in case of liver involvement~  6. Calculated creatinine clearance (CrCl) \> 50 ml/min by Cockcroft-Gault formula~7. Use of an effective means of contraception for women of childbearing potential and men with partners of childbearing potential.~8. Provide written informed consent prior to any study-specific screening procedures.~9. Willingness and capability to comply with the requirements of the study~Exclusion Criteria:~1. Patient receiving anticancer therapy including any investigational therapy ≤3 weeks or 5 half-lives (whichever is shorter) prior to C1D1.~2. Patient who discontinued prior therapy with PI3K inhibitors or HDAC inhibitors due to drug toxicity.~3. PTCL patients with Allo-SCT on active GVHD or immunosuppression therapy within 3 months prior to C1D1. CTCL patients with the history of Allo-SCT will be excluded.~4. Patient with medical conditions requiring the use of systemic immunosuppressive medications (\> 20 mg/day of prednisone or equivalent).~5. Severe bacterial, viral or mycotic infection requiring systemic treatment.~6. Known seropositive requiring anti-viral therapy for human immunodeficiency virus (HIV) infection.~7. Known seropositive requiring anti-viral therapy for hepatitis B virus (HBV) infection OR evidence of active hepatitis B infection as defined by detectable viral load if the antibody tests are positive..~8. Known seropositive requiring anti-viral therapy for hepatitis c virus (HCV) infection OR patients with positive hepatitis C virus Ab.~9. Subjects with active EBV unrelated to underlying lymphoma (positive serology for anti- EBV VCA IgM antibody and negative for anti-EBV EBNA IgG antibody, or clinical manifestations and positive EBV PCR consistent with active EBV infection.~10. Subject with active CMV (positive serology for anti-CMV IgM antibody and negative for anti-CMV IgG antibody and positive CMV PCR with clinical manifestations consistent with active CMV infection) and requiring therapy.~11. Uncontrolled or significant cardiovascular disease including, but not limited to:~    * Congenital long QT syndrome.~   * QTcF interval \> 450 msec~   * Myocardial infarction or stroke/TIA within the past 6 months~   * Uncontrolled angina within the past 3 months~   * Significant ECG abnormalities including 2nd degree atrio- ventricular (AV) block (AV) block type II, 3rd degree AV block.~   * History of clinically significant arrhythmias (such as ventricular tachycardia, ventricular fibrillation or torsades de pointes),~   * History of other clinically significant heart disease (ie, cardiomyopathy, congestive heart failure with NYHA functional classification III-IV, pericarditis, significant pericardial effusion)~   * Requirement for daily supplemental oxygen therapy.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Tenalisib+Romidepsin (Type: EXPERIMENTAL): Participants receive Tenalisib in escalating doses daily Orally BID and Romidepsin in escalating doses intravenously on day 1, 8 and 15

Based on this trial design, predict the completion outcome and termination type (if applicable).